Tagrisso (osimertinib tablets – AstraZeneca) — Cigna
Non-Small Cell Lung Cancer – Unresectable, Stage III
Initial criteria
- Patient age ≥ 18 years
- Patient has locally advanced, unresectable (stage III) disease
- Patient has EGFR exon 19 deletions or exon 21 (L858R) substitution mutation as detected by an approved test
- Patient has not had disease progression during or following platinum-based chemoradiation therapy
- Note: Patient could have received concurrent or sequential chemoradiation therapy
Approval duration
1 year